{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["113(11)"],"submitter":["Donskov F"],"pubmed_abstract":["<h4>Background</h4>Metastatic renal cell carcinoma (mRCC) prognostic models may be improved by incorporating treatment-induced toxicities.<h4>Methods</h4>In sunitinib-treated mRCC patients (N=770), baseline prognostic factors and treatment-induced toxicities (hypertension (systolic blood pressure ⩾140 mm Hg), neutropenia (grade ⩾2), thrombocytopenia (grade ⩾2), hand-foot syndrome (grade >0), and asthenia/fatigue (grade >0)) were analysed in multivariate analyses of progression-free survival (PFS) and overall survival (OS) end points.<h4>Results</h4>On-treatment neutropenia and hypertension were associated with longer PFS (P=0.0276 and P<0.0001, respectively) and OS (P=0.0014 and P<0.0001, respectively), independent of baseline prognostic factors, including International Metastatic Renal Ce"],"journal":["British journal of cancer"],"pagination":["1571-80"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4705883"],"repository":["biostudies-literature"],"pubmed_title":["Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients."],"pmcid":["PMC4705883"],"pubmed_authors":["Bjarnason GA","Michaelson MD","Davis MP","Goldstein D","Lin X","Donskov F","Cohen DP","Puzanov I","Motzer RJ","Wiltshire R","Rini BI"],"additional_accession":[]},"is_claimable":false,"name":"Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.","description":"<h4>Background</h4>Metastatic renal cell carcinoma (mRCC) prognostic models may be improved by incorporating treatment-induced toxicities.<h4>Methods</h4>In sunitinib-treated mRCC patients (N=770), baseline prognostic factors and treatment-induced toxicities (hypertension (systolic blood pressure ⩾140 mm Hg), neutropenia (grade ⩾2), thrombocytopenia (grade ⩾2), hand-foot syndrome (grade >0), and asthenia/fatigue (grade >0)) were analysed in multivariate analyses of progression-free survival (PFS) and overall survival (OS) end points.<h4>Results</h4>On-treatment neutropenia and hypertension were associated with longer PFS (P=0.0276 and P<0.0001, respectively) and OS (P=0.0014 and P<0.0001, respectively), independent of baseline prognostic factors, including International Metastatic Renal Ce","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Dec","modification":"2025-04-18T16:27:36.827Z","creation":"2019-03-27T02:06:34Z"},"accession":"S-EPMC4705883","cross_references":{"pubmed":["26492223"],"doi":["10.1038/bjc.2015.368"]}}